32 research outputs found
Erratum
Response to alpha 2B interferon treatment in a haemodialysis patient with chronic hepatitis C. The complete list of authors contributing to the above letter should have appeared as follows: G. Barril, J. A. Schez Tomero, L. Garcia Buey, J. L. Motellon, C. Bernis and J. A. Trave
Head-to-head comparison of length of stay, patients' outcome and satisfaction in Switzerland before and after SwissDRG-Implementation in 2012 in 2012: an observational study in two tertiary university centers.
On 1 January 2012 Swiss Diagnosis Related Groups (DRG), a new uniform payment system for in-patients was introduced in Switzerland with the intention to replace a "cost-based" with a "case-based" reimbursement system to increase efficiency. With the introduction of the new payment system we aim to answer questions raised regarding length of stay as well as patients' outcome and satisfaction.
This is a prospective, two-centre observational cohort study with data from University Hospital Basel and the Cantonal Hospital Aarau, Switzerland, from January to June 2011 and 2012, respectively. Consecutive in-patients with the main diagnosis of either community-acquired pneumonia, exacerbation of COPD, acute heart failure or hip fracture were included. A questionnaire survey was sent out after discharge investigating changes before and after SwissDRG implementation. Our primary endpoint was LOS.
Of 1,983 eligible patients 841 returned the questionnaire and were included into the analysis (429 in 2011, 412 in 2012). The median age was 76.7 years (50.8% male). Patients in the two years were well balanced in regard to main diagnoses and co-morbidities. Mean LOS in the overall patient population was 10.0 days and comparable between the 2011 cohort and the 2012 cohort (9.7 vs 10.3; p = 0.43). Overall satisfaction with care changed only slightly after introduction of SwissDRG and remained high (89.0% vs 87.8%; p = 0.429).
Investigating the influence of the implementation of SwissDRG in 2012 regarding LOS patients' outcome and satisfaction, we found no significant changes. However, we observed some noteworthy trends, which should be monitored closely
Maladies et complément [Complement in diseases]
The complement system is part of the innate immunity. It is a multifunctional system including more than 30 plasma and membrane proteins. These are activated by an enzymatic cascade and proteolytic reactions producing activating fragments. Complement is : 1) among the first line of defense towards a pathogen, 2) increasing efficacy of the acquired immunity, 3) responsible for the elimination of immune complexes apoptotic and or necrotic cells (waste removal function) and many other cellular and tissue functions. The aim of this article is to analyze the consequences of complement dysregulation in the development of various diseases
Circulating Immune Complex Levels are Associated with Disease Severity and Seasonality in Children with Malaria from Mali
A monoclonal antibody which blocks the function of factor D of human complement.
Factor D is an essential enzyme for activation of complement by the alternative pathway (AP). It has been difficult to obtain mouse monoclonal antibodies (Mabs) which block the function of factor D. We have developed a strategy to obtain such Mabs using a double screening procedure of the initial clones. We selected the clone whose supernatant had the lowest level of anti-factor D Ab by ELISA and abolished factor D haemolytic activity. Addition of this Mab to human serum was shown to abolish conversion of C3 by cobra venom factor, haemolysis of rabbit erythrocytes, and activation of C3 and C5 by cuprophane dialysis membranes